Once you have been diagnosed with carcinoid syndrome, your doctor will recommend a treatment, such as Sandostatin® LAR Depot (octreotide acetate) for injectable suspension. Sandostatin LAR Depot is a prescription medicine for the long-term treatment of the severe diarrhea and flushing associated with metastatic carcinoid tumors.
 |
Two Different Formulations Sandostatin is available in 2 formulations, which are administered differently: |
|
1 |
Sandostatin® (octreotide acetate) Immediate-Release Injection, which you self-inject 2 to 4 times per day under the skin of the thigh, upper arm, or abdomen. |
|
2 |
Sandostatin® LAR Depot (octreotide acetate) for injectable suspension, which your health care provider administers once every 28 days by injecting it into the buttocks. |
Your doctor will decide if Sandostatin LAR Depot is right for you based on how your body responds to Sandostatin Immediate-Release Injection.
How Sandostatin Works
Sandostatin works directly at the site of metastatic carcinoid tumors to help decrease the production of hormones that lead to the severe diarrhea and flushing associated with carcinoid syndrome.
Some Facts About Sandostatin
The active ingredient in Sandostatin, called octreotide acetate, works by blocking the production of a number of hormones that can lead to the symptoms of severe diarrhea and flushing associated with carcinoid syndrome
It is the first FDA-approved somatostatin medication for the severe diarrhea and flushing associated with carcinoid syndrome*
The effect of Sandostatin Immediate-Release Injection and Sandostatin LAR Depot on tumor size, rate of growth and development of metastases has not been determined
*Includes Sandostatin Immediate-Release Injection and Sandostatin LAR Depot for all approved indications.
Warnings and Precautions: Treatment with Sandostatin LAR Depot may affect gallbladder function, with postmarketing reports of gallstones resulting in complications...
Sandostatin® LAR Depot (octreotide acetate) for injectable suspension is indicated for patients in whom initial treatment with immediate-release Sandostatin® ...